title: Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy.
abstract: BACKGROUND
  Assessment of overall health is a critical component in the evaluation of patients presenting with clinically localized prostate cancer. Estimated glomerular filtration rate (eGFR) has been associated with increased risk of cardiovascular and overall mortality. Therefore, the objective of our study was to evaluate the impact of baseline renal function on oncologic outcomes and overall survival following radical prostatectomy.
  
  
  METHODS
  We identified 10,099 patients who underwent radical prostatectomy at our institution from 1990 to 2004 with a preoperative serum creatinine available for analysis. eGFR was calculated by the chronic kidney disease-epidemiology formula (CKD-EPI) and reported as ml/min per 1.73 m(2). Patients were then classified according to their eGFR: <30, 30-59, 60-89, 90-119, and 120-150 ml/min/1.73 m(2). Multivariate Cox proportional hazard regression models were used to analyze the impact of eGFR on postoperative outcomes.
  
  
  RESULTS
  At the time of surgery, 25 patients (0.1%) had an eGFR <30 ml/min/1.73 m(2), 2,398 (23.7%) between 30 and 60, 7,097 (70.3%) between 60 and 90, and 605 (6.0%) patients had an eGFR >90. eGFR was not associated with oncologic outcomes, including biochemical recurrence, systemic progression or cancer-specific survival (P > 0.05 for all). However, eGFR was strongly associated with all-cause mortality and non-prostate cancer death. On multivariate analysis, after controlling for age, BMI, prostate-specific antigen doubling time (PSA), Gleason score, and clinical stage, eGFR remains a statistically significant predictor of all-cause mortality.
  
  
  CONCLUSIONS
  Assessment of eGFR is an important metric in the overall evaluation of patient health and should be considered in combination with patient age and other medical comorbidities when selecting the initial treatment of prostate cancer. While prostate cancer-specific outcomes do not appear to be impacted by renal function, overall survival is decreased in those with lower and higher than normal eGFR.
authors.affiliation: Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA. Electronic address: garfield@vern.edu.
authors.forename: Matthew K
authors.initials: MK
authors.lastname: Tollefson
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Boorjian
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Gettman
authors.forename: Laureano J
authors.initials: LJ
authors.lastname: Rangel
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Bergstralh
authors.forename: R Jeffrey
authors.initials: RJ
authors.lastname: Karnes
mesh_terms: D000368:Aged; D015992:Body Mass Index; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D057234:Preoperative Period; D011379:Prognosis; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate
chemical_list: D017430:Prostate-Specific Antigen